Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Mucosal bacteria in ulcerative colitis.

S Macfarlane1, E Furrie, A Kennedy

  • 1Microbiology and Gut Biology Group, University of Dundee, Dundee DD1 9SY, UK. s.macfarlane@dundee.ac.uk

The British Journal of Nutrition
|May 10, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characterisation and comparison of Mycoplasma bovis strain types from Irish and Scottish bovine isolates in a global context.

Veterinary microbiology·2024
Same author

Microplastic in Dredged Sediments: From Databases to Strategic Responses.

Bulletin of environmental contamination and toxicology·2024
Same author

Developing priorities for quality improvement in acute medicine using a modified Delphi method A consensus process hosted by the Society for Acute Medicine Quality Improvement Committee (SAM-QI).

Acute medicine·2022
Same author

Society for Acute Medicine Benchmarking Audit 2021 (SAMBA21): assessing national performance of acute medicine services.

Acute medicine·2022
Same author

Length of stay in Acute Medical Admissions: Analysis from the Society for Acute Medicine Benchmarking Audit.

Acute medicine·2022
Same author

National population prevalence of antibodies to SARS-CoV-2 in Scotland during the first and second waves of the COVID-19 pandemic.

Public health·2021

Synbiotic therapy using Bifidobacterium longum and Synergy 1 increased beneficial bifidobacteria in ulcerative colitis (UC) patients. This treatment reduced inflammation markers in the rectal mucosa, suggesting a potential therapeutic approach for UC.

Area of Science:

  • Gastroenterology
  • Microbiology
  • Immunology

Background:

  • Ulcerative colitis (UC) is a chronic inflammatory bowel disease where colonic microbiota play a role.
  • Mucosa-associated bacteria are implicated more than luminal bacteria due to proximity to the epithelium.
  • Reduced bifidobacteria in UC patients suggest a potential protective role.

Purpose of the Study:

  • To investigate mucosal bacteria differences in UC patients versus healthy controls.
  • To develop and test a synbiotic therapy aimed at increasing bifidobacteria and reducing inflammation in UC.
  • To evaluate the impact of synbiotic treatment on mucosal microbiota and immune markers in active UC.

Main Methods:

  • Comparative bacteriological analysis of rectal biopsies from UC patients and controls.

Related Experiment Videos

  • Development of a synbiotic (Bifidobacterium longum and oligofructose-enriched inulin - Synergy 1).
  • A randomized controlled trial using the synbiotic in active UC patients, with pre- and post-treatment biopsy analysis.

    • Main Results:

    • Significant reductions in bifidobacteria were observed in UC patients compared to controls.
    • Synbiotic treatment led to increased bifidobacterial colonization of the rectal mucosa.
    • The treatment significantly reduced the expression of inflammation-controlling molecules in active UC.

    Conclusions:

    • Synbiotic therapy with Bifidobacterium longum and Synergy 1 is effective in modulating the mucosal microbiota in UC.
    • This approach increases beneficial bifidobacteria and reduces inflammation in active ulcerative colitis.
    • Synbiotics represent a promising therapeutic strategy for managing ulcerative colitis.